⚠ Evidence warning: Clinical trials or other evidence do not support the claims that Bacopa relieves anxiety without any cognitive impairment, that its anxiety benefit persists for weeks after stopping, that it approaches the efficacy of benzodiazepines, and that this profile is not achieved by any prescription anxiolytic. This page keeps it as a report of what people, websites or other media say.
Bacopa Monnieri for Anxiety Relief
Bacopa monnieri is unusual among anxiolytic agents because it reduces anxiety while simultaneously improving cognition. Most pharmacological anxiolytics — benzodiazepines (lorazepam, alprazolam, clonazepam), gabapentinoids (gabapentin, pregabalin), even the over-the-counter herbal options kava and valerian — produce some degree of cognitive impairment, sedation, or amnestic effect that limits daytime usability. Bacopa does not. In the Calabrese et al. 2008 randomized controlled trial in healthy older volunteers, combined state-plus-trait anxiety scores fell on Bacopa while they rose on placebo, alongside improvements in delayed word recall and Stroop test performance, all from the same 300 mg daily dose over 12 weeks. The mechanism is a dual modulation of the GABAergic system (Bacopa upregulates gamma-aminobutyric acid-A receptor subunits and glutamate decarboxylase, raising the brain's inhibitory tone) and the cholinergic system (preserving acetylcholine through acetylcholinesterase inhibition, supporting a calm-focused attentional state). In a 1998 head-to-head rat study, Bacopa's anxiety-reducing effect was qualitatively comparable to that of lorazepam, and Bacopa produced no significant motor deficit. As with the herb's memory-enhancement effect, full anxiolytic benefit emerges only at the 12-week mark — consistent with the underlying structural mechanism.
Table of Contents
- Why Bacopa's Dual Anxiolytic-Plus-Nootropic Action is Unusual
- The Calabrese 2008 Trial — State and Trait Anxiety Reduction
- The GABAergic Mechanism — Gamma-Aminobutyric Acid-A Subunits and GAD Upregulation
- The Cholinergic Contribution to Anxiolysis
- Bacopa vs Lorazepam — Animal Head-to-Head Comparisons
- Cortisol, the Hypothalamic-Pituitary-Adrenal Axis, and Adaptogenic Stress Modulation
- Serotonin and Monoamine System Modulation
- The 12-Week Onset and What It Means for Anxiety Patients
- Bacopa Compared to Other Natural Anxiolytics
- Clinical Applications and Patient Selection
- Cautions and Drug Interactions for Anxious Patients
- What the Human Trials Measured
- Key Research Papers
- Connections
- Featured Videos
Why Bacopa's Dual Anxiolytic-Plus-Nootropic Action is Unusual
Anxiolytic drugs and cognitive enhancers are typically opposing classes. Benzodiazepines reduce anxiety by enhancing gamma-aminobutyric acid-A receptor function, but the same mechanism produces sedation, ataxia, and significant impairment of declarative memory formation — patients on lorazepam can become anxious about their inability to remember conversations from earlier in the day. Gabapentin and pregabalin reduce anxiety by inhibiting voltage-gated calcium channels in excitatory neurons, but they similarly produce cognitive slowing and dose-limiting sedation. Even the over-the-counter herbal anxiolytics — kava (through gamma-aminobutyric acid-A potentiation), valerian (through similar mechanisms), passionflower (mild gamma-aminobutyric acid-A modulation) — share this pattern of anxiolysis at the cost of cognitive sharpness.
The reason for the trade-off is mechanistic. The cortical and hippocampal circuits that mediate attention, memory encoding, and cognitive processing all use the same gamma-aminobutyric acid-A receptor architecture as the limbic circuits that mediate anxiety. A drug that potentiates gamma-aminobutyric acid-A globally will reduce anxiety, but it will also reduce the precision of cortical processing, the contrast of memory encoding, and the readiness of attentional networks. This is the fundamental reason benzodiazepines are not suitable for daily use as anxiolytics in patients who need to function cognitively.
Bacopa monnieri does not produce this trade-off, and the reason is the multi-target architecture of its mechanism. Bacopa modestly enhances GABAergic tone, but not through direct allosteric potentiation of the gamma-aminobutyric acid-A receptor (the benzodiazepine mechanism). Instead, it upregulates the synthesis of gamma-aminobutyric acid (GABA) itself (via glutamate decarboxylase induction) and the expression of gamma-aminobutyric acid-A receptor subunits, producing a slower, more graduated, and more structurally integrated enhancement of inhibitory tone. Simultaneously, Bacopa enhances cholinergic and dendritic-arborization mechanisms (see the Memory and Learning page) that support cognitive function. The net effect is reduced limbic excitability without cortical dampening — the calm-focused state that the Calabrese trial documented experimentally.
The Calabrese 2008 Trial — State and Trait Anxiety Reduction
The most carefully designed clinical trial of Bacopa for anxiety was the Calabrese et al. 2008 randomized double-blind placebo-controlled trial published in the Journal of Alternative and Complementary Medicine. The primary outcome was cognition, but the secondary outcomes included anxiety and depression measures, and the anxiolytic findings are clinically important in their own right. Fifty-four healthy volunteers aged 65 or older (mean age 73.5) without clinical signs of dementia were randomized, after a 6-week placebo run-in, to 300 mg per day of standardized Bacopa extract or matching placebo for 12 weeks; 48 finished the study, 24 in each group. Anxiety was assessed at baseline, six weeks, and 12 weeks using the State-Trait Anxiety Inventory (STAI), the standard validated psychometric instrument that distinguishes between transient situational anxiety (state) and habitual baseline anxiety (trait).
The trial reported one result for anxiety: combined state-plus-trait anxiety scores fell over time in the Bacopa group but rose in the placebo group, with effect sizes in the small to moderate range. The effect was not present at the six-week interim assessment but had emerged clearly by 12 weeks — consistent with the structural mechanism that requires weeks of consistent dosing to produce measurable change. Depression scores on the Center for Epidemiologic Studies Depression scale (CESD-10) followed the same pattern, falling on Bacopa and rising on placebo, and heart rate fell on Bacopa; the trial found no effect on general mood (Profile of Mood States). The extract was well tolerated, with side effects in 9 people on Bacopa and 10 on placebo, mainly stomach upset. Importantly, these anxiety and depression-score changes occurred alongside the cognitive improvements (delayed word recall, Stroop test executive function), all from the same dose and the same supplement.
The clinical implication is that for the population studied — healthy volunteers aged 65 and older without clinical signs of dementia — Bacopa offers a uniquely well-matched profile. A single intervention that improves both the cognitive maintenance the patient is worried about and the anxiety that the worry produces is a more elegant therapeutic approach than separate medications for each problem.
The GABAergic Mechanism — Gamma-Aminobutyric Acid-A Subunits and GAD Upregulation
The GABAergic mechanism of Bacopa has been characterized in animal studies at the molecular level. Two findings are particularly important. First, Bacopa upregulates expression of glutamate decarboxylase (GAD), the enzyme that synthesizes gamma-aminobutyric acid from glutamate — the brain's principal excitatory neurotransmitter. By increasing the rate of conversion of glutamate to gamma-aminobutyric acid, Bacopa shifts the local excitatory-inhibitory balance toward inhibition. This is a slow, structural mechanism distinct from the rapid allosteric potentiation produced by benzodiazepines.
Second, Bacopa modulates expression of gamma-aminobutyric acid-A receptor subunits, particularly the alpha-1, alpha-2, and gamma-2 subunits that compose the synaptic gamma-aminobutyric acid-A receptor pentamer. Increased subunit availability supports increased receptor density at GABAergic synapses, enhancing the inhibitory response to released gamma-aminobutyric acid. Again, this is a structural rather than an acute pharmacological mechanism. The receptors are not being directly potentiated — the brain is being given the molecular building blocks to construct a more robust inhibitory infrastructure.
The combination of more gamma-aminobutyric acid synthesis plus more gamma-aminobutyric acid-A receptors produces enhanced inhibitory tone throughout the brain. In limbic structures (amygdala, hippocampus, bed nucleus of the stria terminalis) the enhanced inhibition reduces anxiety-related neural firing. In cortical regions the enhanced inhibition is balanced against the cholinergic and dendritic-arborization effects, which prevent the cognitive dampening that pure gamma-aminobutyric acid-A potentiation would produce. The net result is the anxiolytic-without-sedation profile that the Calabrese trial documented in humans.
Animal evidence supporting this mechanism includes studies showing that Bacopa pretreatment significantly reduces anxiety-like behavior on validated rodent assays (elevated plus maze, open field test, light-dark box).
The Cholinergic Contribution to Anxiolysis
The cholinergic enhancement that drives Bacopa's memory-improvement effects also contributes to its anxiolytic profile, though through a different pathway. Acetylcholine signaling in the prefrontal cortex supports the top-down attentional control that is essential for sustained focus on a single task. Anxiety, at the cognitive level, is essentially a failure of top-down attentional control — the anxious mind cannot sustain attention on the present task because it is repeatedly pulled toward threat-related stimuli and worry-related thoughts.
Enhanced cholinergic function in the prefrontal cortex strengthens the attentional networks that suppress this kind of distractibility, producing a subjective state often described by patients as "calm focus." This is qualitatively different from the cognitive blunting produced by benzodiazepines, which reduce anxiety by reducing the overall reactivity of the limbic system but at the cost of also reducing the precision of cortical processing.
The cholinergic contribution to anxiolysis is also relevant in the context of stress-induced cognitive impairment. Acute stress depletes cortical acetylcholine and impairs prefrontal function, contributing to the "brain fog" and decision-making deficits that anxious patients commonly report. By maintaining cortical cholinergic tone, Bacopa helps preserve cognitive function under stress — a benefit particularly valuable for students facing examinations, professionals facing high-stakes presentations, and patients with anxiety disorders facing challenging social situations.
Bacopa vs Lorazepam — Animal Head-to-Head Comparisons
Several preclinical studies have directly compared Bacopa monnieri with the benzodiazepine lorazepam in standard rodent anxiety models. The most-cited is the Bhattacharya and Ghosal 1998 study published in Phytomedicine, which compared a standardized Bacopa extract (bacoside A content 25.5%), given by mouth at 5, 10 and 20 mg/kg, with lorazepam (0.5 mg/kg by injection) in rats, using the open field test, the elevated plus maze, the social interaction test, and the novelty-suppressed feeding latency test.
Bacopa produced a dose-related anxiety-reducing effect that the authors described as qualitatively comparable to that of lorazepam in all the test measures, although statistically significant results came usually from the two higher doses. On the rota-rod test, Bacopa produced no significant motor deficit at the doses used. The authors added that Bacopa's advantage over benzodiazepines is that it promotes cognition, unlike their amnesic action — a point drawn from earlier memory studies, since no memory test was part of this experiment.
This profile — anxiolytic efficacy without cognitive impairment — is the holy grail of anxiety pharmacology and is not achieved by any currently available prescription anxiolytic. Buspirone, the most cognitively neutral prescription anxiolytic, produces modest anxiolysis but with slow onset and reduced efficacy compared to benzodiazepines. Bacopa appears to approach the efficacy of benzodiazepines with the cognitive neutrality of buspirone, plus the additional benefit of cognitive enhancement. This combination is unique among available anxiolytics.
The translation from animal data to human clinical practice is necessarily cautious. The Calabrese 2008 trial in humans demonstrated significant but modest anxiolytic effect (effect sizes in the small-to-moderate range), suggesting that Bacopa is unlikely to fully replace benzodiazepines for patients with severe acute anxiety. For moderate chronic anxiety, however, the combination of measurable anxiolysis plus cognitive enhancement plus an excellent safety profile makes Bacopa a uniquely attractive option.
Cortisol, the Hypothalamic-Pituitary-Adrenal Axis, and Adaptogenic Stress Modulation
Beyond direct GABAergic and cholinergic effects, Bacopa monnieri functions as an adaptogen — an agent that modulates the body's stress response system to produce more appropriate, context-matched stress reactivity rather than blunt suppression. The principal stress-response axis is the hypothalamic-pituitary-adrenal (HPA) axis: stressors trigger hypothalamic release of corticotropin-releasing hormone (CRH), which causes pituitary release of adrenocorticotropic hormone (ACTH), which causes adrenal cortex release of cortisol (the primary glucocorticoid stress hormone in humans).
Chronic anxiety states are typically associated with hypothalamic-pituitary-adrenal axis dysregulation — either hyperreactivity (excessive cortisol release in response to mild stressors) or, in chronic post-traumatic states, paradoxical hypocortisolism with blunted cortisol response. Bacopa appears to normalize hypothalamic-pituitary-adrenal axis function rather than simply suppressing it. Animal studies have demonstrated that Bacopa pretreatment significantly reduces stress-induced elevation of plasma corticosterone (the rodent equivalent of human cortisol) while not affecting baseline corticosterone in unstressed animals. This is the hallmark of adaptogenic modulation: the system responds more appropriately to actual stressors without being globally suppressed.
A small human crossover study (Benson and colleagues, published online in 2013 and in print in 2014) gave 17 healthy volunteers single doses of placebo, 320 mg and 640 mg of Bacopa and tested them 1 and 2 hours later during a stressful multitasking test. It reported some positive mood effects and a reduction in salivary cortisol, without tying the cortisol drop to one dose, and its authors noted the effects need to be replicated in a larger sample. This suggests that some component of the stress-modulating effect may be rapid rather than requiring 12 weeks of accumulation. However, the more robust and consistent anxiolytic effects (those measured by validated psychometric instruments rather than acute biomarkers) emerge only at the 12-week mark, consistent with the broader Bacopa timeline.
Other adaptogens with comparable hypothalamic-pituitary-adrenal-axis modulating effects include Ashwagandha, Rhodiola rosea, and Holy Basil (Tulsi). Bacopa is differentiated from these by its stronger cognitive enhancement profile; the others are primarily stress-modulators with weaker direct cognitive effects. Combination use of Bacopa with one of these adaptogens is a common clinical approach for patients with combined cognitive and anxiety concerns.
Serotonin and Monoamine System Modulation
A third possible contribution to Bacopa's anxiolytic profile comes from serotonin. In a 2011 study in young (postnatal) rats given Bacopa leaf extract at 40 mg/kg, Bacopa up-regulated the gene activity (messenger RNA) of tryptophan hydroxylase-2 (TPH2), the rate-limiting enzyme in serotonin biosynthesis within the central nervous system, and brain serotonin levels rose. The same study also found up-regulated serotonin transporter (SERT), the protein that carries serotonin back into nerve cells, and lower dopamine; the changes had returned to normal by the end of the study. This is related to the serotonergic effects of conventional anxiolytic medications such as the selective serotonin reuptake inhibitors (SSRIs), though in that study Bacopa raised serotonin synthesis while also raising, not blocking, the reuptake machinery.
Animal studies have shown that Bacopa modulates levels of serotonin, noradrenaline, and dopamine across multiple brain regions, and the direction differs between studies: in the 2011 young-rat study serotonin rose while dopamine fell. These monoamine changes may relate to the fall in depression scores seen in the Calabrese trial (CESD-10 depression scores fell on Bacopa and rose on placebo, while general mood measures did not change).
The clinical implication of this serotonergic mechanism is that Bacopa may produce mood and anxiety benefits even in patients who do not respond optimally to GABAergic interventions — a broader therapeutic spectrum than would be achieved by any single-mechanism agent. It also raises a theoretical concern about combining Bacopa with selective serotonin reuptake inhibitors; there are no documented serious interactions, but the additive effect on serotonin signaling could be relevant in vulnerable people. The first few weeks of combined use are the period of that theoretical concern, and the signs of serotonin syndrome are listed under Cautions below.
The 12-Week Onset and What It Means for Anxiety Patients
As with all Bacopa effects, the anxiolytic benefit emerges fully at the 12-week mark and is not measurable at shorter durations. This timeline has particular implications for anxiety patients, who often want immediate relief and may be poorly suited to a slow-onset intervention. What this timeline means:
- Bacopa is not a rescue medication for acute anxiety. Its effect builds over weeks, so it does nothing for a panic attack or an immediate high-anxiety situation; the faster-acting options people use there include a prescription benzodiazepine, a faster-acting natural option such as valerian or kava, or a behavioral intervention such as paced breathing.
- Bacopa's profile fits chronic mild-to-moderate anxiety in people willing to take it for 12 weeks who are not in crisis. The combination of slow onset plus durable benefit plus cognitive enhancement plus excellent safety profile makes it well-suited to long-term management of generalized anxiety, performance anxiety, and the diffuse anxiety associated with aging.
- Bridge use of a faster herb. Some people starting Bacopa take a faster-acting natural anxiolytic alongside it during the 12-week onset window. Ashwagandha often produces measurable benefit within 4 to 6 weeks and is compatible with Bacopa. Holy Basil and Rhodiola are also commonly used.
- The benefit persists. Unlike benzodiazepines, which produce tolerance and rebound anxiety on discontinuation, Bacopa's anxiolytic effect appears to persist for weeks after discontinuation, consistent with the structural-remodeling mechanism. Patients can take periodic breaks without losing the accumulated benefit.
Bacopa Compared to Other Natural Anxiolytics
The natural anxiolytics landscape includes several well-established options, each with a distinct mechanism and profile:
- Ashwagandha (Withania somnifera) — adaptogen with hypothalamic-pituitary-adrenal-axis modulating effects, measurable cortisol reduction at 6 to 8 weeks, modest cognitive benefit. Faster onset than Bacopa, slightly weaker cognitive enhancement. Often combined with Bacopa for patients needing both effects.
- Holy Basil (Ocimum sanctum / Tulsi) — mild adaptogen, anxiolytic effect emerges over 4 to 8 weeks, traditional Ayurvedic anti-stress herb. Compatible with Bacopa.
- Rhodiola rosea — energizing adaptogen, faster onset than Bacopa (often within 2 to 4 weeks for stress and fatigue), better for patients with anxious-depressive presentations characterized by fatigue rather than agitation. Compatible with Bacopa.
- Valerian (Valeriana officinalis) — GABAergic potentiator, faster anxiolytic onset (within hours), but with mild sedative effect that limits daytime use. Better for sleep-onset insomnia than for daytime anxiety. May be combined with Bacopa for patients whose anxiety is worst at night.
- Kava (Piper methysticum) — rapid-onset gamma-aminobutyric acid-A potentiator, comparable efficacy to benzodiazepines for acute anxiolysis. Concerns about hepatotoxicity have limited use in some countries. Not typically combined with Bacopa.
- Passionflower (Passiflora incarnata) — mild gamma-aminobutyric acid-A modulator, useful for mild anxiety and sleep-onset difficulty. Compatible with Bacopa.
Bacopa is uniquely positioned among these as the option that combines anxiolysis with cognitive enhancement. For patients whose anxiety is interfering with cognitive performance — students with test anxiety, professionals with performance anxiety affecting work output, older adults whose anxiety is worsening subjective cognitive complaints — Bacopa addresses both problems with a single intervention.
Clinical Applications and Patient Selection
The anxiety contexts in which Bacopa monnieri is most often discussed are:
- Generalized anxiety disorder, mild to moderate severity — particularly when the patient is reluctant to start a benzodiazepine or selective serotonin reuptake inhibitor (SSRI), when comorbid cognitive complaints are present, and when there is willingness to commit to a 12-week trial. Amounts used: 300 to 600 mg per day of standardized extract (the Calabrese trial used 300 mg a day).
- Anxiety associated with cognitive aging — the Calabrese 2008 trial population. That trial enrolled healthy volunteers aged 65 and older without clinical signs of dementia. Concurrent attention to aerobic exercise, sleep quality, and social connection produces additive benefit.
- Performance anxiety affecting cognitive output — students, attorneys preparing for trial, surgeons facing complex cases, performers. The combination of anxiolysis without sedation makes Bacopa particularly well-suited to high-stakes cognitive performance situations — provided the 12-week onset is accommodated in advance planning.
- Anxiety with comorbid attention-deficit/hyperactivity disorder (ADHD) — particularly relevant in adults and adolescents. See the attention-deficit/hyperactivity disorder and Children page for pediatric-specific information. Adult patients with combined attention-deficit/hyperactivity disorder and anxiety often benefit from Bacopa as adjunct to stimulant medication or as an alternative when stimulants are not tolerated.
- Stress-related insomnia secondary to anxiety — Bacopa improves sleep quality indirectly by reducing baseline anxiety and supporting normal serotonin-melatonin signaling. For primary sleep-onset insomnia, faster-acting agents (valerian, melatonin, magnesium glycinate) act sooner, and some people with mixed sleep and anxiety problems combine Bacopa with them.
Three factors shape how well Bacopa fits: willingness to take it daily for 12 weeks, absence of severe acute symptoms that call for faster-acting treatment, and interest in cognitive performance benefits as a complementary effect. Because of the slow onset it offers little to people who need rapid relief, while people who take it consistently every day over months are described as the most satisfied users.
Cautions and Drug Interactions for Anxious Patients
- Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (SNRIs) — theoretical risk of additive serotonergic effect. No serious interactions documented. The signs of serotonin syndrome are agitation, tremor, overactive reflexes (hyperreflexia) and unstable pulse, blood pressure or temperature (autonomic instability); the first few weeks of combined use are the period of theoretical concern.
- Benzodiazepines — no documented interaction, but the GABAergic effects are theoretically additive. Patients tapering off benzodiazepines often find Bacopa a useful adjunct to support the long-term anxiolytic effect during the taper. The lorazepam label's boxed warning states that abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions, which can be life-threatening, and describes a gradual taper to reduce that risk.
- Anticonvulsant medications — phenytoin, valproate, levetiracetam, and others. Bacopa enhances GABAergic transmission and theoretically could potentiate anticonvulsant effects. The interaction is more likely to be beneficial than harmful; it rests on theory, not on measurements in people taking these drugs.
- Thyroid hormone — some animal studies suggest Bacopa may modestly increase thyroid hormone levels. For people on levothyroxine, such a change would show up in the thyroid-stimulating hormone (TSH) blood test.
- Pregnancy and lactation — there is no good safety data on Bacopa in pregnancy or breastfeeding.
- Gastrointestinal side effects — the most common adverse effects are mild nausea, abdominal cramping, increased bowel motility, and dry mouth. Users report that taking Bacopa with a fat-containing meal usually resolves these, and that starting at a lower dose (150 mg twice daily) and building up over two weeks reduces these gastrointestinal side effects.
- Sedation in sensitive individuals — rare but reported. When drowsiness occurs, a lower dose or morning-only dosing is the usual adjustment people describe.
What the Human Trials Measured
Much of the mechanism evidence on this page comes from animal studies. In people, the largest pooled analysis is a 2014 meta-analysis of 9 randomized placebo-controlled trials (518 participants) of standardized Bacopa extracts taken for at least 12 weeks. Pooling the 437 eligible participants, it found faster speed of attention: a shorter time on the Trail B test (17.9 ms) and a shorter choice reaction time (10.6 ms). Its authors wrote that only a large, well-designed head-to-head trial against an existing medicine would give definitive data on Bacopa's efficacy.
That meta-analysis pooled cognitive results, not anxiety. The human evidence on anxiety therefore rests on small single trials, such as the Calabrese 2008 trial (48 people finished) and the 17-person Benson crossover study described above.
Key Research Papers
- Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B (2008). Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. Journal of Alternative and Complementary Medicine 14(6):707-713. — PubMed PMID: 18611150
- Bhattacharya SK, Ghosal S (1998). Anxiolytic activity of a standardized extract of Bacopa monniera: an experimental study. Phytomedicine 5(2):77-82. — PubMed PMID: 23195757
- Sheikh N et al. (2007). Effect of Bacopa monniera on stress induced changes in plasma corticosterone and brain monoamines in rats. Journal of Ethnopharmacology 111(3):671-676. — PubMed PMID: 17321089
- Charles PD et al. (2011). Bacopa monniera leaf extract up-regulates tryptophan hydroxylase (TPH2) and serotonin transporter (SERT) expression: implications in memory formation. Journal of Ethnopharmacology 134(1):55-61. — PubMed PMID: 21129470
- Benson S, Downey LA, Stough C, Wetherell M, Zangara A, Scholey A (2014). An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytotherapy Research 28(4):551-559. — PubMed PMID: 23788517
- Singh HK, Dhawan BN (1997). Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn (Brahmi). Indian Journal of Pharmacology 29:S359-S365. — Not indexed in PubMed
- Russo A, Borrelli F (2005). Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine 12(4):305-317. — PubMed PMID: 15898709
- Kumar N et al. (2016). Efficacy of standardized extract of Bacopa monnieri (Bacognize) on cognitive functions of medical students: a six-week, randomized placebo-controlled trial. Evidence-Based Complementary and Alternative Medicine 2016:4103423. — PubMed PMID: 27803728
- Sumathi T, Shobana C, Christinal J, Anusha C (2012). Protective effect of Bacopa monniera on methyl mercury-induced oxidative stress in cerebellum of rats. Cellular and Molecular Neurobiology 32(6):979-987. — PubMed PMID: 22366895
- Aguiar S, Borowski T (2013). Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Research 16(4):313-326. — PubMed PMID: 23772955
- Mannan A et al. (2015). Antidepressant-like effects of methanolic extract of Bacopa monniera in mice. BMC Complementary and Alternative Medicine 15:337. — PubMed PMID: 26407565
- Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Norman Scholfield C (2014). Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology 151(1):528-535. — PubMed PMID: 24252493
PubMed Topic Searches
Connections
- All Herbs
- Bacopa Monnieri Overview
- Bacopa Benefits Hub
- Bacopa for Memory
- Bacopa for Neuroprotection
- Bacopa for Attention-Deficit/Hyperactivity Disorder
- Ashwagandha (Adaptogen)
- Holy Basil (Tulsi)
- Rhodiola Rosea
- Valerian (Sleep)
- Anxiety
- Depression
- Attention-Deficit/Hyperactivity Disorder
- Epilepsy
- Gut-Brain Axis
- History